NEW YORK, May 10, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE: TXMD). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether TherapeuticsMD and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On April 10, 2017, the Company announced that it had received a letter from the U.S. Food and Drug Administration ("FDA") on April 7, 2017, stating that, as part of its ongoing review of the Company's New Drug Application submission for TX-004HR, a treatment of moderate-to-severe dyspareunia, the FDA had identified deficiencies that preclude discussion of the drug's labeling and postmarketing requirements/commitments.
On this news, TherapeuticsMD's share price fell $1.50, or 19.48%, to close at $6.20 on April 19, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
Robert S. Willoughby
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-therapeuticsmd-inc--txmd-300455263.html
SOURCE Pomerantz LLP